EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries

N J Simmonds, S C Charman, J Wosniok, C Haugh, D Santoro, S Fiorini, R Charretier, C Sanchez, C Procaccianti, L Naehrlich

Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 621-627

DOI: 10.1016/j.jcf.2026.03.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von N J Simmonds und 9 weiteren Autor:innen. Beteiligte Einrichtung: Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Ki…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Levofloxacin, Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiesi Pharmaceuticals SpA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Levofloxacin inhalation solution (LIS) is approved for managing chronic Pseudomonas aeruginosa infections in adult patients with cystic fibrosis (CF). The European Medicines Agency made a provisional marketing authorisation of LIS conditional on its long-term safety evaluation in clinical practice. METHODS: The safety of LIS was evaluated using data from the UK (2017-2021) and German CF Registries (2019-2021). Propensity score models were used to compare the LIS cohorts (patients treated with LIS at any time during observation) with the non-LIS cohorts (treated with other inhaled antibiotics). Primary endpoints included haemoptysis, liver disease, tendon rupture, antimicrobial resistance and treatment discontinuation. RESULTS: In the UK Registry, 103 and 511 adult patients were included in the LIS and non-LIS cohorts, respectively. In the German Registry, equivalent numbers were 524 and 1893. In the UK, no significant difference in haemoptysis rates was observed between the LIS and non-LIS cohorts (17.5% vs 19.6%, adjusted relative risk [aRR]: 0.88, 95%CI 0.56-1.39, P=0.583). In the German Registry, a higher risk of haemoptysis was observed in the LIS cohort (17% vs 12%; aRR: 1.30, 95%CI 1.06-1.59, P=0.012). There was no increased risk of liver disease associated with LIS treatment, and tendon ruptures were rare. Antimicrobial resistance patterns were similar in LIS and non-LIS cohorts, and treatment discontinuation due to adverse events was low in both registries. CONCLUSIONS: LIS was generally safe although may be associated with a higher risk of haemoptysis. No difference in liver disease, tendon rupture or treatment discontinuation compared to other inhaled antibiotics was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisLevofloxacinAnti-Bacterial AgentsPseudomonas InfectionsHumansGermanyFemaleUnited KingdomRegistriesAdministration, InhalationAdultMaleHemoptysis

Stichwörter der Autor:innen

Cystic fibrosisHaemoptysisInhaled antibioticsLevofloxacin inhalation solutionLiver disease

Substanzen

LevofloxacinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom. Electronic address: nicholasjames.simmonds@nhs.net.
  • Cystic Fibrosis Trust, London, United Kingdom.
  • Interdisciplinary Center for Clinical Trials Mainz, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Global Clinical Development, Chiesi Farmaceutici S.p.A., Parma, Italy.
  • Global Regulatory Affairs and Patient Safety, Chiesi Farmaceutici S.p.A., Parma, Italy.
  • Global Clinical Development, Chiesi SAS, Paris, France.

Förderung

  • Chiesi Pharmaceuticals SpA

Zitieren

APA

Simmonds, N. J., Charman, S. C., Wosniok, J., Haugh, C., Santoro, D., Fiorini, S., Charretier, R., Sanchez, C., Procaccianti, C., & Naehrlich, L. (2026). Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries. Journal of Cystic Fibrosis, 25(4), 621-627. https://doi.org/10.1016/j.jcf.2026.03.012

Vancouver

Simmonds NJ, Charman SC, Wosniok J, Haugh C, Santoro D, Fiorini S, et al. Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries. Journal of Cystic Fibrosis. 2026;25(4):621-627. doi:10.1016/j.jcf.2026.03.012

BibTeX
@article{Simmonds2026,
  author = {Simmonds, N J and Charman, S C and Wosniok, J and Haugh, C and Santoro, D and Fiorini, S and Charretier, R and Sanchez, C and Procaccianti, C and Naehrlich, L},
  title = {Safety of inhaled levofloxacin in people with cystic fibrosis: Data from UK and German Registries},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  volume = {25},
  number = {4},
  pages = {621--627},
  doi = {10.1016/j.jcf.2026.03.012}
}
Kostenlos starten →